Florida Attorney General Issues Subpoena to CVS Health in Pharmacy Probe -- Barrons.com

Dow Jones
06/24

By Catherine Dunn

The Florida attorney general's office said on Tuesday that it's probing the relationship between CVS Health's retail pharmacies and its pharmacy benefit manager, or PBM, business. The announcement adds another pressure point to an industry under bipartisan scrutiny across states and in Washington, including calls to break up ownership of PBMs and pharmacies by the same company.

PBMs help decide which drugs are covered by an insurance plan, in addition to managing the pharmacy networks where consumers fill prescriptions. The industry says it plays an important role in managing healthcare costs for clients, such as large employers that sponsor health plans, and a plan's members.

Florida AG James Uthmeier said he is examining whether CVS's PBM steers patients to its own pharmacies and pays its pharmacies higher reimbursements than it pays to independent pharmacies. Those practices allegedly contribute to pharmacy closures, "leaving families and seniors with fewer options and higher costs," the AG's office said.

"Here you have a situation where it appears one company has gotten so big that they are controlling market power in a way that might manipulate pricing at the cost of consumers," Uthmeier said during a press conference.

As part of the probe, the state attorney general issued a civil investigative demand to CVS Health with a July 28 deadline. The subpoena requests documents and sworn testimony covering pharmacy contracts, reimbursement rates, "differential treatment of own versus independent stores," and the company's expansion plans, according to a press release. CVS operates about 800 pharmacies in Florida.

A spokesman for CVS said the company "will work with the Florida Attorney General to address any concerns."

"Independent pharmacies remain vital to CVS Caremark's networks, and we collaborate with them to ensure all members have convenient access to the care they need," spokesman David Whitrap told Barron's. "We welcome the opportunity to work with regulators and policymakers to set the record straight around these market dynamics, and more importantly, to improve consumer experience and affordability."

Write to Catherine Dunn at catherine.dunn@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

June 23, 2026 17:33 ET (21:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10